Emobio

EmoBio is a biotechnology company headquartered in Suzhou, China, dedicated to the research and development of exosome-based therapeutics and diagnostics. The company utilizes a proprietary platform for the engineering of extracellular vesicles, aiming to create highly targeted drug delivery systems for oncology and inflammatory disorders. EmoBio's technology focuses on the efficient loading of therapeutic payloads, such as nucleic acids and proteins, into exosomes to improve bioavailability and safety profiles. Furthermore, the company is developing advanced liquid biopsy solutions that utilize exosomal biomarkers for the early detection and monitoring of various cancers. EmoBio aims to bridge the gap between basic exosome research and clinical application through its "Exosome+" strategy.